Tesamorelin 10mg

Tesamorelin is a stabilized analog of human growth hormone-releasing hormone (GHRH) consisting of the complete 44-amino acid sequence with an added trans-3-hexenoic acid modification. This structural enhancement significantly increases the compound's stability and half-life, making it highly suitable for both acute and chronic research protocols investigating the somatotropic axis. Research suggests Tesamorelin selectively stimulates pituitary somatotroph cells to synthesize and release endogenous growth hormone in a physiologically pulsatile manner. This makes it an invaluable tool for studies examining GH secretion dynamics, IGF-1 pathway activation, and body composition changes—particularly visceral adipose tissue regulation. Research Applications Growth hormone secretion studies IGF-1 pathway research Body composition investigations Visceral adipose tissue studies Pituitary function research For scientific research purposes only. Not for human consumption.

FDA-approved for: - HIV-associated lipodystrophy - Visceral adipose reduction - Cognitive function (research) - NAFLD/NASH treatment - Cardiovascular health - Muscle preservation - Bone density - Quality of life improvement

Synthetic GHRH analog: 1. Binds to GHRH receptors 2. Stimulates pituitary GH release 3. Increases IGF-1 production 4. Preserves physiological pulsatility 5. Reduces visceral fat specifically 6. Maintains feedback mechanisms 7. Minimal effect on glucose

Reduced visceral adipose tissue Improved body composition Maintained muscle mass Better lipid profiles Improved cognitive function Enhanced quality of life Cardiovascular benefits Preserved bone density

FDA-approved dosing: - Standard: 2mg daily subcutaneously - Administration: Inject into abdomen - Timing: Bedtime preferred - Duration: Continuous use - Monitor IGF-1 levels regularly

Common side effects: - Injection site reactions (most common) - Joint pain - Muscle pain - Swelling/edema - Paresthesia - Rash - Hyperglycemia (monitor) - IGF-1 elevation